Header Logo

Connection

Philip Bonomi to Carcinoma, Non-Small-Cell Lung

Back to Details
This is a "connection" page, showing publications Philip Bonomi has written about Carcinoma, Non-Small-Cell Lung.
Philip Bonomi
Connection Strength
15.689
Carcinoma, Non-Small-Cell Lung
  1. Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis. Curr Med Res Opin. 2020 09; 36(9):1497-1505.
    View in: PubMed
    Score: 0.593
  2. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. Ann Oncol. 2018 08 01; 29(8):1701-1709.
    View in: PubMed
    Score: 0.517
  3. Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients. Ann Oncol. 2016 08; 27(8):1612-9.
    View in: PubMed
    Score: 0.444
  4. Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015 Feb; 10(2):353-9.
    View in: PubMed
    Score: 0.406
  5. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer. 2015 Mar 15; 121(6):883-92.
    View in: PubMed
    Score: 0.399
  6. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol. 2013 Mar; 8(3):338-45.
    View in: PubMed
    Score: 0.355
  7. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2013 Jul; 14(4):370-5.
    View in: PubMed
    Score: 0.350
  8. Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Anticancer Res. 2012 May; 32(5):1705-10.
    View in: PubMed
    Score: 0.335
  9. PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy. Br J Cancer. 2011 Dec 06; 105(12):1920-6.
    View in: PubMed
    Score: 0.325
  10. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol. 2011 Jun; 6(6):1079-86.
    View in: PubMed
    Score: 0.315
  11. Epidermal growth factor receptor pathway. J Thorac Oncol. 2010 Dec; 5(12 Suppl 6):S470-1.
    View in: PubMed
    Score: 0.304
  12. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Rev Anticancer Ther. 2010 Oct; 10(10):1589-99.
    View in: PubMed
    Score: 0.300
  13. Implications of key trials in advanced nonsmall cell lung cancer. Cancer. 2010 Mar 01; 116(5):1155-64.
    View in: PubMed
    Score: 0.288
  14. Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. J Thorac Oncol. 2009 Jul; 4(7):869-74.
    View in: PubMed
    Score: 0.275
  15. Treatment of locally advanced non-small cell lung cancer. Clin Adv Hematol Oncol. 2009 Jul; 7(7):455-64, 479-80.
    View in: PubMed
    Score: 0.275
  16. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009 Jul 10; 27(20):3284-9.
    View in: PubMed
    Score: 0.273
  17. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer. 2008 May 20; 98(10):1608-13.
    View in: PubMed
    Score: 0.255
  18. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res. 2008 Apr 01; 14(7):2088-94.
    View in: PubMed
    Score: 0.253
  19. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J Clin Oncol. 2007 Sep 01; 25(25):3936-44.
    View in: PubMed
    Score: 0.243
  20. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 2):s4606-12.
    View in: PubMed
    Score: 0.241
  21. The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. J Thorac Oncol. 2007 May; 2(5):414-22.
    View in: PubMed
    Score: 0.237
  22. Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer. Expert Rev Anticancer Ther. 2007 Apr; 7(4):415-22.
    View in: PubMed
    Score: 0.236
  23. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol. 2006 Nov 20; 24(33):5253-8.
    View in: PubMed
    Score: 0.230
  24. Other compounds and targets in non-small cell lung cancer. Semin Oncol. 2005 Dec; 32(6 Suppl 10):S30-6.
    View in: PubMed
    Score: 0.215
  25. Therapeutic advances in second-line treatment of advanced non-small-cell lung cancer. Clin Lung Cancer. 2004 Nov; 6(3):154-61.
    View in: PubMed
    Score: 0.199
  26. Locally advanced NSCLC: current state of the art, treatment and future directions. J Natl Compr Canc Netw. 2004 Sep; 2 Suppl 2:S23-30.
    View in: PubMed
    Score: 0.197
  27. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol. 2004 Aug 15; 22(16):3238-47.
    View in: PubMed
    Score: 0.196
  28. Novel treatments in non-small cell lung cancer. Hematol Oncol Clin North Am. 2004 Feb; 18(1):245-67.
    View in: PubMed
    Score: 0.189
  29. Epidermal growth factor receptor-targeted therapy and symptom improvement in non-small cell lung cancer. Am J Health Syst Pharm. 2003 Dec 15; 60(24 Suppl 9):S16-21.
    View in: PubMed
    Score: 0.188
  30. Clinical studies with non-iressa EGFR tyrosine kinase inhibitors. Lung Cancer. 2003 Aug; 41 Suppl 1:S43-8.
    View in: PubMed
    Score: 0.183
  31. Erlotinib: a new therapeutic approach for non-small cell lung cancer. Expert Opin Investig Drugs. 2003 Aug; 12(8):1395-401.
    View in: PubMed
    Score: 0.183
  32. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 4):78-86.
    View in: PubMed
    Score: 0.165
  33. Novel approaches for the treatment of non-small cell lung cancer. Semin Oncol. 2001 Aug; 28(4 Suppl 14):45-9.
    View in: PubMed
    Score: 0.159
  34. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition. J Immunol Methods. 2021 03; 490:112956.
    View in: PubMed
    Score: 0.153
  35. Chemoradiation in locally advanced non-small cell lung cancer. Cancer Treat Res. 2001; 105:171-88.
    View in: PubMed
    Score: 0.153
  36. Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586). Am J Clin Oncol. 2000 Aug; 23(4):371-5.
    View in: PubMed
    Score: 0.148
  37. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb; 18(3):623-31.
    View in: PubMed
    Score: 0.143
  38. Review of paclitaxel/carboplatin in advanced non-small cell lung cancer. Semin Oncol. 1999 Feb; 26(1 Suppl 2):55-9.
    View in: PubMed
    Score: 0.134
  39. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol. 2019 02 01; 37(4):278-285.
    View in: PubMed
    Score: 0.133
  40. Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. Clin Cancer Res. 2019 01 01; 25(1):64-72.
    View in: PubMed
    Score: 0.130
  41. The serum-based VeriStrat? test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer. 2018 03 20; 18(1):310.
    View in: PubMed
    Score: 0.126
  42. Development of bead based multiplexed immunoassay for evaluation of midkine, syndecan-1, and ANGPTL4 in patient serum. J Immunoassay Immunochem. 2018; 39(1):84-98.
    View in: PubMed
    Score: 0.125
  43. Eastern Cooperative Oncology Group experience with chemotherapy in advanced non-small cell lung cancer. Chest. 1998 Jan; 113(1 Suppl):13S-16S.
    View in: PubMed
    Score: 0.124
  44. Recent advances with chemotherapy for NSCLC: the ECOG experience. Eastern Cooperative Oncology Group. Oncology (Williston Park). 1998 Jan; 12(1 Suppl 2):67-70.
    View in: PubMed
    Score: 0.124
  45. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. J Thorac Oncol. 2018 02; 13(2):165-183.
    View in: PubMed
    Score: 0.123
  46. Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer. Oncology (Williston Park). 1997 Apr; 11(4 Suppl 3):9-10.
    View in: PubMed
    Score: 0.118
  47. Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer. BMC Cancer. 2017 02 16; 17(1):141.
    View in: PubMed
    Score: 0.117
  48. Escalating paclitaxel doses combined with carboplatin/etoposide and thoracic radiotherapy as preoperative or definitive treatment for stage III non-small cell lung cancer. Semin Oncol. 1996 Dec; 23(6 Suppl 16):102-7.
    View in: PubMed
    Score: 0.115
  49. Clinicopathologic Features of Advanced Squamous NSCLC. J Thorac Oncol. 2016 09; 11(9):1411-22.
    View in: PubMed
    Score: 0.111
  50. The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial. J Thorac Oncol. 2016 Jun; 11(6):808-18.
    View in: PubMed
    Score: 0.110
  51. Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer. Am J Clin Oncol. 2015 Dec; 38(6):605-9.
    View in: PubMed
    Score: 0.107
  52. Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response. J Thorac Oncol. 2015 Oct; 10(10):1475-80.
    View in: PubMed
    Score: 0.106
  53. Carboplatin/etoposide/radiation plus escalating doses of paclitaxel in stage III non-small cell lung cancer: a preliminary report. Semin Oncol. 1995 Aug; 22(4 Suppl 9):42-7.
    View in: PubMed
    Score: 0.105
  54. Combined modality treatment for stage III non-small cell lung cancer. Lung Cancer. 1995 Jun; 12 Suppl 2:S41-52.
    View in: PubMed
    Score: 0.104
  55. Survival Prediction in Ambulatory Patients With Stage III/IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale. Am J Hosp Palliat Care. 2016 May; 33(4):374-80.
    View in: PubMed
    Score: 0.102
  56. Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by?Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2015 May; 16(3):200-8.
    View in: PubMed
    Score: 0.100
  57. Treatment of stage III non-small cell lung cancer with thoracic radiation therapy and simultaneous platinum chemotherapy. Semin Oncol. 1994 Jun; 21(3 Suppl 6):101-8.
    View in: PubMed
    Score: 0.097
  58. Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer. An Eastern Cooperative Oncology Group study. Am J Clin Oncol. 1994 Jun; 17(3):215-7.
    View in: PubMed
    Score: 0.097
  59. Alteration of integrated optical density and intercellular structure after induction chemotherapy and survival in lung carcinoma patients treated surgically. Anal Quant Cytol Histol. 1994 Feb; 16(1):18-24.
    View in: PubMed
    Score: 0.095
  60. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy. Pract Radiat Oncol. 2014 Sep-Oct; 4(5):342-348.
    View in: PubMed
    Score: 0.094
  61. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 Dec 01; 31(34):4349-57.
    View in: PubMed
    Score: 0.093
  62. Radiation and simultaneous cisplatin in non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1993 Oct 20; 27(3):739-46.
    View in: PubMed
    Score: 0.093
  63. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013 Jun 01; 19(11):3068-77.
    View in: PubMed
    Score: 0.089
  64. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Diagn Mol Pathol. 2012 Dec; 21(4):207-13.
    View in: PubMed
    Score: 0.087
  65. Platinum/etoposide therapy in non-small cell lung cancer. Oncology. 1992; 49 Suppl 1:43-50.
    View in: PubMed
    Score: 0.082
  66. Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancer. Ann Thorac Surg. 2011 Nov; 92(5):1805-11; discussion 1811.
    View in: PubMed
    Score: 0.080
  67. Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. Ann Thorac Surg. 2011 Jul; 92(1):233-41; discussion 241-3.
    View in: PubMed
    Score: 0.079
  68. Prognostic importance of subdividing clinically staged IIIa and IIIb patients with non-small-cell lung cancer. J Clin Oncol. 1991 Feb; 9(2):357-9.
    View in: PubMed
    Score: 0.077
  69. Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment. Int J Radiat Oncol Biol Phys. 1991 Feb; 20(2):247-52.
    View in: PubMed
    Score: 0.077
  70. Carboplatin in non-small cell lung cancer: review of the Eastern Cooperative Oncology Group trial and comparison with other carboplatin trials. Semin Oncol. 1991 Feb; 18(1 Suppl 2):2-7.
    View in: PubMed
    Score: 0.077
  71. Recent advances in etoposide therapy for non-small cell lung cancer. Cancer. 1991 Jan 01; 67(1 Suppl):254-9.
    View in: PubMed
    Score: 0.076
  72. Concurrent chemotherapy and thoracic irradiation in non-small cell lung cancer. Hematol Oncol Clin North Am. 1990 Dec; 4(6):1143-58.
    View in: PubMed
    Score: 0.076
  73. Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers. Int J Cancer. 2011 Jul 01; 129(1):133-42.
    View in: PubMed
    Score: 0.076
  74. Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):985-91.
    View in: PubMed
    Score: 0.075
  75. A multi-analyte serum test for the detection of non-small cell lung cancer. Br J Cancer. 2010 Oct 12; 103(8):1221-8.
    View in: PubMed
    Score: 0.075
  76. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res. 2010 Jul 01; 16(13):3452-62.
    View in: PubMed
    Score: 0.074
  77. Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer. Lung Cancer. 2011 Feb; 71(2):186-90.
    View in: PubMed
    Score: 0.073
  78. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer. 2010 Apr 01; 126(7):1630-9.
    View in: PubMed
    Score: 0.073
  79. Neoadjuvant treatment in locally advanced non-small cell lung cancer. Semin Surg Oncol. 1990; 6(5):255-62.
    View in: PubMed
    Score: 0.071
  80. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol. 1989 Nov; 7(11):1602-13.
    View in: PubMed
    Score: 0.070
  81. Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does "side" really matter? Ann Thorac Surg. 2009 Sep; 88(3):937-43; discussion 944.
    View in: PubMed
    Score: 0.070
  82. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer. 2009 Jul; 10(4):252-6.
    View in: PubMed
    Score: 0.069
  83. A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer. Am J Clin Oncol. 2009 Jun; 32(3):269-73.
    View in: PubMed
    Score: 0.068
  84. Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer. J Thorac Oncol. 2009 Mar; 4(3):338-47.
    View in: PubMed
    Score: 0.067
  85. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2008 Nov 20; 26(33):5407-15.
    View in: PubMed
    Score: 0.066
  86. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer. 2008 Jul; 61(1):82-90.
    View in: PubMed
    Score: 0.062
  87. Phase II trial of therapy with etoposide, 5-fluorouracil by continuous infusion, cisplatin, and simultaneous split-course radiation in stage III non-small cell bronchogenic carcinoma. NCI Monogr. 1988; (6):331-4.
    View in: PubMed
    Score: 0.062
  88. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol. 2007 Oct 20; 25(30):4743-50.
    View in: PubMed
    Score: 0.061
  89. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol. 2007 Aug 10; 25(23):3448-55.
    View in: PubMed
    Score: 0.060
  90. Phase II trial of mitomycin, vindesine, and hexamethylmelamine in metastatic non-small cell bronchogenic carcinoma. Cancer Treat Rep. 1986 Dec; 70(12):1447-8.
    View in: PubMed
    Score: 0.058
  91. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiother Oncol. 2006 Nov; 81(2):163-7.
    View in: PubMed
    Score: 0.057
  92. Brief overview of combination chemotherapy in non-small-cell lung cancer. Semin Oncol. 1986 Sep; 13(3 Suppl 3):89-91.
    View in: PubMed
    Score: 0.057
  93. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial. Lung Cancer. 2006 Jul; 53(1):77-83.
    View in: PubMed
    Score: 0.056
  94. PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. Clin Lung Cancer. 2006 May; 7(6):417-9.
    View in: PubMed
    Score: 0.055
  95. Current strategies in the management of lung cancer. Oncology (Williston Park). 2005 Nov; 19(13):1667-8.
    View in: PubMed
    Score: 0.053
  96. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005 Sep 01; 23(25):5883-91.
    View in: PubMed
    Score: 0.053
  97. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol. 2005 Jan 01; 23(1):175-83.
    View in: PubMed
    Score: 0.050
  98. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol. 2003 Apr 15; 21(8):1536-43.
    View in: PubMed
    Score: 0.045
  99. ZD0473 treatment in lung cancer: an overview of the clinical trial results. Eur J Cancer. 2002 Dec; 38 Suppl 8:S13-8.
    View in: PubMed
    Score: 0.044
  100. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 2002 Mar; 55(3):285-95.
    View in: PubMed
    Score: 0.041
  101. Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. Ann Oncol. 2000 Jun; 11(6):673-8.
    View in: PubMed
    Score: 0.037
  102. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol. 2000 Jan; 18(1):131-5.
    View in: PubMed
    Score: 0.036
  103. A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (PZ586). Lung Cancer. 1999 Sep; 25(3):199-206.
    View in: PubMed
    Score: 0.035
  104. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Clin Cancer Res. 1999 Apr; 5(4):767-74.
    View in: PubMed
    Score: 0.034
  105. Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials. Stat Med. 1998 Mar 15-Apr 15; 17(5-7):781-96.
    View in: PubMed
    Score: 0.031
  106. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587). Cancer. 1998 Jan 15; 82(2):292-300.
    View in: PubMed
    Score: 0.031
  107. Post-operative adjuvant therapy for non-small-cell lung cancer. Lung Cancer. 1997 Jun; 17 Suppl 1:S23-5.
    View in: PubMed
    Score: 0.030
  108. Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy. J Neuromuscul Dis. 2017; 4(2):169-173.
    View in: PubMed
    Score: 0.029
  109. Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group study (E2588). Invest New Drugs. 1995; 13(2):137-41.
    View in: PubMed
    Score: 0.025
  110. Combined modality treatment using BID radiation for locally advanced non-small cell lung carcinoma. Cancer. 1994 May 15; 73(10):2599-606.
    View in: PubMed
    Score: 0.024
  111. Combined modality therapy for stage III non-small cell lung carcinoma: results of treatment and patterns of failure. Int J Radiat Oncol Biol Phys. 1992; 24(1):17-23.
    View in: PubMed
    Score: 0.020
  112. Combined modality therapy for locally advanced non-small cell lung carcinoma. Cancer. 1990 Dec 01; 66(11):2270-8.
    View in: PubMed
    Score: 0.019
  113. Preoperative radiation therapy in regionally localized stage III non-small cell lung carcinoma: long-term results and patterns of failure. Int J Radiat Oncol Biol Phys. 1990 Aug; 19(2):287-92.
    View in: PubMed
    Score: 0.019
  114. Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg. 1989 May; 47(5):669-75; discussion 676-7.
    View in: PubMed
    Score: 0.017
  115. Preoperative combined modality therapy for stage III M0 non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1988 Jul; 15(1):189-95.
    View in: PubMed
    Score: 0.016
  116. Concomitant therapy with infusion of cisplatin and 5-fluorouracil plus radiation in stage III non-small cell lung cancer. NCI Monogr. 1988; (6):327-9.
    View in: PubMed
    Score: 0.016
  117. Modification of the effects of cytotoxic chemotherapy on the immune responses of cancer patients with a nonsteroidal, antiinflammatory drug, piroxicam. A pilot study of the Eastern Cooperative Oncology Group. J Biol Response Mod. 1987 Jun; 6(3):331-45.
    View in: PubMed
    Score: 0.015
  118. Simultaneous cisplatin fluorouracil infusion and radiation followed by surgical resection in regionally localized stage III, non-small cell lung cancer. Ann Thorac Surg. 1987 Jan; 43(1):87-91.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.